Michael Barbella, Managing Editor06.30.23
Kurin Inc. has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Kurin product line. The clearance—the firm's fourth—says, in part, that Kurin reduces the frequency of blood culture contaminations.*
“We are pleased the FDA has provided clearance to say that Kurin reduces blood culture contaminations” Kurin CEO Bob Rogers said. “Kurin is the market leader because our device is simple to use and requires a minimal amount of blood. Our submission to the FDA included data demonstrating dramatic decreases in contaminations while using Kurin. The new 510(k) highlights Kurin’s growing list of accomplishments and underscores why Kurin continues to be the #1 company addressing blood culture contaminations. This is yet further proof that the myth that blood must be isolated to achieve contamination reduction is simply wrong.”
Kurin’s approach to the contaminated blood culture problem is a simple intuitive design that requires no additional user steps. Kurin passively sidelines potential contaminants during blood culture collection. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and life-threatening C. diff. infections.
San Diego-based Kurin Inc., a certified Minority Business Enterprise (MBE), designs, develops, manufactures, markets, and sells products that help healthcare providers reduce contaminated blood cultures.
* Kurin Lock allows the specimen of blood from the patient to be sidelined prior to the collection of the test sample to reduce the frequency of blood culture contamination when contaminates are present in the initial blood sample compared to blood cultures drawn using standard practice without the Kurin Lock.
“We are pleased the FDA has provided clearance to say that Kurin reduces blood culture contaminations” Kurin CEO Bob Rogers said. “Kurin is the market leader because our device is simple to use and requires a minimal amount of blood. Our submission to the FDA included data demonstrating dramatic decreases in contaminations while using Kurin. The new 510(k) highlights Kurin’s growing list of accomplishments and underscores why Kurin continues to be the #1 company addressing blood culture contaminations. This is yet further proof that the myth that blood must be isolated to achieve contamination reduction is simply wrong.”
Kurin’s approach to the contaminated blood culture problem is a simple intuitive design that requires no additional user steps. Kurin passively sidelines potential contaminants during blood culture collection. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and life-threatening C. diff. infections.
San Diego-based Kurin Inc., a certified Minority Business Enterprise (MBE), designs, develops, manufactures, markets, and sells products that help healthcare providers reduce contaminated blood cultures.
* Kurin Lock allows the specimen of blood from the patient to be sidelined prior to the collection of the test sample to reduce the frequency of blood culture contamination when contaminates are present in the initial blood sample compared to blood cultures drawn using standard practice without the Kurin Lock.